A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)

PHASE2CompletedINTERVENTIONAL

Enrollment

832

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

Symptomatic Gastroespohageal Reflux Disease

Interventions

DRUG

Tegaserod

Trial Locations (1)

Novartis, East Hanover